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5-fluorouracil (5-FU) is a pyrimidine analog that has been successfully employed in 
anticancer therapy for over forty years.  Over the past several decades, researchers have 
characterized its cellular and clinical pharmacology and uncovered multiple mechanisms of 
action, which include the inhibition of thymidylate synthase (TS) and incorporation of its 
metabolites into DNA and RNA.  The purpose of this quantitative systemic review was to 
summarize and evaluate what is known of these mechanisms to determine which are of most 
significance in the anticancer effects of 5-FU in metastatic colorectal cancer (mCRC) patients.  A 
literature search of peer-reviewed articles dating back to the discovery of 5-FU did not find 
evidence to conclusively satisfy this inquiry, mainly due to a lack of relevant research in human 
models and uncertainty regarding the impact of DNA and RNA repair processes in tumor cells 
following drug administration.  Overall, the literature did not support the current assumption that 
DNA-based mechanisms are definitively most responsible for the efficacy of 5-FU, and 
underscores the importance of better understanding how 5-FU promotes cell death and how 
tumors develop resistance to it.  Future research could be directed toward further elucidating the 
mechanistic details of 5-FU treatment in humans, as well as discovering clinically useful 
biomarkers to better optimize and personalize metastatic colorectal cancer therapies.    
Introduction 
Worldwide, colorectal cancer is the 2nd and 3rd most common cancer in females and 
males, respectively.  Metastatic disease at diagnosis is found in up to 25% of colorectal cancer 
patients, and up to an additional 60% of patients develop metastases following initial therapy.3  
Once metastasis has occurred, treatment of colorectal cancer consists of chemotherapy to extend 
and improve quality of life, rather than to cure.  
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For decades now, the first-line chemotherapeutic for mCRC has been intravenous 5-FU, 
an anticancer agent believed to most significantly disrupt the DNA pathways of metastatic 
cancer cells.  The most widely used dosing and duration regimens for 5-FU were developed in 
the late 1990’s.4  Other chemotherapeutics have since been added to these regimens, with the 
intention of amplifying its DNA-directed effects.  However, more recent discoveries indicate 5-
FU may rely heavily on RNA-directed mechanisms for its anticancer effects.  If true, this would 
mean clinicians should utilize additional methods of combination therapy to better accentuate the 
drug’s RNA-based effects, rather than focus on reinforcing its impact on cancer cell DNA.2,3   
This review will summarize what is known about the mechanisms of 5-FU efficacy, 
while seeking to explore whether its effects are primarily due to DNA-based activity, or whether 
RNA-directed effects also play an important role.  I hypothesize recent research shows 5-FU 
effects RNA pathways in mCRC in a fashion significant enough to warrant reconsideration of 
clinical combination strategies for colorectal cancer patients.  Objectives of this review also 
include discussing research recommendations related to furthering our understanding of how 5-
FU works, and briefly exploring the future of colorectal cancer therapy in terms of more 
specialized and personalized therapeutic options. 
Background: Literature Review 
 Discovery.  5-FU is an example of a rationally designed fluoropyrimidine 
chemotherapeutic.  The observation in 1954 that rat hepatomas incorporated radiolabeled uracil 
during nucleic acid biosynthesis more avidly than nonmalignant tissues implied that malignant 
cells would be more sensitive to cytotoxic agents that mimic uracil than are normal cells.5  Based 
on the hypothesis that uracil is preferentially used by cancer cells, and on speculation that a 
uracil analog might alter cancer cell metabolism, multiple uracil and uridine derivatives were 
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synthesized and then tested for antagonist activity against tumors.6  5-FU was one such 
discovered antimetabolite agent.  While metabolites of other developed antimetabolite drugs 
either inhibited essential biosynthetic processes, or incorporated into DNA or RNA, 5-FU 
metabolites appeared to do both.  Shortly after its discovery, the efficacy of 5-FU as a potential 
anti-tumor drug was reported, and it has since been tested in numerous clinical trials and found 
to exhibit DNA-based anti-tumor activity in patients.1,3,6 
A deoxyribonucleic derivative of 5-FU, 5-fluoro-2′-deoxyuridine (FdUrd), was also 
synthesized.  In 1977, Corbett et al performed in vivo research on humans comparing FdUrd with 
5-FU.  Using various schedules of administration on patients with human colon tumors, these 
experiments yielded more than three times as many tumor-free survivors following FdUrd 
treatment.7  Since then, this derivative has consistently been shown to be more effective than 5-
FU in many cancer cell lines and rat models, and is FDA-approved for the treatment of hepatic 
colon metastases.8,9  However, while FdUrd has exhibited better antitumor activity, 5-FU 
provokes less systemic toxicity in humans and is less expensive, resulting in the restricted usage 
of FdUrd.10  One of its common uses includes experimentally examining the effects of 5-FU as 
an equivalent stand-in.6  However, there are many subtle chemical differences between the two 
agents that raise questions as to the validity of such experimentation, which is crucial to keep in 
mind when reviewing 5-FU research.  This topic will be further addressed in the discussion 
section. 
Development of Treatment Schedules.  As a small molecule, 5-FU generally exhibits 
excellent absorption.  However, its oral administration was abandoned decades ago due to 
unpredictable catabolism and bioavailability.10  When 5-FU therapy was first developed in the 
United States, it was usually administered intravenously via a bolus schedule.  Later studies 
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showed that 5-FU was a time-dependent drug whereby greater cytotoxicity correlated with 
longer exposure.  For example, the activity of 5-FU against HT-29 cancer cells in vitro was three 
times higher when the drug was present for longer times at lower doses as compared with higher 
doses for shorter times.6  As a result, therapeutic strategies in the late 1990’s were developed 
around infusion schedules to allow for longer-term systemic therapy.  However, the resulting 
modest increase in efficacy did not immediately lead to changes in 5-FU-based treatment tactics 
due mainly to increased toxicity.  As combination strategies incorporating agents that modulate 
the effects of 5-FU were developed, which allowed for improved patient safety alongside 
increased treatment intensity, non-bolus infusion schedules were utilized more.6  Currently, 5-FU 
is only used in combination with other therapeutics, which underlines the importance of finding 
the best complementary drugs to optimize results.  FOLFIRI (5-FU, leucovorin, and irinotecan) 
and FOLFOX (5-FU, leucovorin, and oxaliplatin) therapies, each based on non-bolus infusion of 
5-FU every other week for 6 months, have become the most commonly used standard regimens 
for late-stage colorectal cancer.3,4,12   
Potential Mechanisms of Action.  Production of the active metabolites 5-fluorouridine-
5'-triphosphate (FUTP), 5-fluorouridine-5′-monophosphate (FdUMP), and 5-fluoro-2′-
deoxyuridine-5′-triphosphate (FdUTP) appears to be critical for 5-FU-based effects (Figure 1).  
FUTP is extensively incorporated into RNA, disrupting normal RNA processing and function.  
FdUMP and FdUTP, on the other hand, interfere with DNA processing and function.  FdUMP 
also inhibits the function of thymidylate synthase (TS), an enzyme that is essential for DNA 
synthesis.2,13  In the scientific literature, TS inhibition is often referenced in terms of a significant 
DNA-based mechanism of 5-FU anticancer activity. 
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While both RNA- and DNA-directed effects have been associated with normal tissue 
toxicity and antitumor efficacy, the role of each in the outcome of 5-FU treatment remain to be 
established.  To further complicate matters, the extent to which these mechanisms predominate 
in human tumor or normal cells varies across cell types and with different methods and doses of 
drug administration.1,6,14  The following is a summary of the cell line-, animal-, and clinical-
based evidence for and against the significance of RNA- and DNA-based mechanisms following 
5-FU treatment. 
RNA-Directed Mechanisms.  The 5-FU metabolite FUTP resembles uridine-5'-
triphosphate (UTP) during RNA transcription and is recognized by RNA polymerases, leading to 
FUTP incorporation into all types of RNA.  Research shows that this incorporation affects RNA 
metabolism in multiple ways.  First, it leads to the inhibition of some RNA biogenesis.  Rapidly 
growing cells, such as tumor cells, need vigorous RNA biogenesis pathways to continuously 
build up ribonucleoprotein complexes.  FUTP incorporation stabilizes pseudouridylases in these 
complexes, inhibiting the conversion of uridine to pseudouridine.  This limits the cell’s capacity 
to modify and produce RNA precursors, such as pre-mRNAs and rRNAs, which in turn limits 
RNA production.13  FUTP incorporation additionally disrupts post-transcriptional modification 
of tRNAs, and the assembly and activity of small nuclear RNA and protein complexes, thereby 
inhibiting the splicing of pre-mRNA, which also limits further RNA production.14  Second, RNA 
marked by FUTP incorporation is less likely to be recognized by surveillance machinery, and is 
thus not degraded at the appropriate times or levels.  Third, 5-FU-based incorporation into RNA 
reduces the cellular levels of the nuclear exosome Rrp6, a complex that degrades RNA, 
preventing the efficient recycling of abnormal RNA transcripts.  This results in the accumulation 
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of irregular RNA intermediates, which has been shown to associate with chromosomal instability 
for unknown reasons.13 
In summary, the activity of 5-FU at the RNA level is the result of at least three effects: 
the reduced synthesis of RNA and its precursors, the inhibition of the nuclear RNA surveillance 
pathway, and the increased levels of intermediate elements with mutagenic potential.13,14  
However, while FUTP incorporation into RNA accounts for over 90% of overall 5-FU-based 
incorporation in most cells, the consequences of this accumulation have not been extensively 
studied and its true effects on RNA function remain poorly understood.10 
Potential Clinical Significance of RNA-Directed Mechanisms.  As early as 1973, 5-FU 
was shown in vitro to inhibit pre-RNA processing in rat hepatoma cells, which correlated with 
the stopping of protein synthesis and resulted in apoptosis processes.2  More recent murine and 
human cancer cell line studies have confirmed that 5-FU-based FUTP incorporation into RNA 
inhibits net RNA and protein synthesis in a concentration and time dependent manner, thought to 
be due mainly to inhibition of RNA biogenesis.13  Significant relationships between 5-FU 
incorporation into RNA, structural RNA modifications, and loss of clonogenic potential have 
also been shown in human colon and breast cancer cell lines.2  Such findings suggest that 
atypical RNA processing and maturation is an important aspect of 5-FU cytotoxicity. 
However, other in vitro evidence shows that 5-FU incorporation does not fully interfere 
with nuclear RNA maturation or functioning, including research illustrating that fluorinated 
nucleotides can be found in mature RNA, and can even remain for considerable periods of time 
in patient colon tumor RNA (at least 3 days)15 and in mice colon tumor RNA (at least 1 week),16 
without detrimental effects.  This suggests that, while incorporation into RNA may be 
quantitatively significant, it might not disturb normal RNA-based processes in these models.  
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Also, other colorectal cell line experimentation suggests that protein expression associated with 
5-FU-based cytotoxicity is independent of 5-FU-based incorporation into RNA, furthering the 
notion that incorporation into RNA is not responsible for related cellular effects.16,17 
Clinically, it has been reported that there was no significant relationship between 5-FU 
metabolite incorporation into RNA and response to 5-FU treatment.10  Overall, the significance 
of 5-FU-mediated RNA alterations and the precise mechanism(s) by which they result in 
cytotoxic events remain uncertain both in cell lines and clinically.  One reason for this is the 
general lack of understanding about the mechanisms of 5-FU-based RNA misincorporation; 
another is the lack of research designed to elucidate these mechanisms.10, 17 
DNA-Directed Mechanisms.  5-FU is believed to affect DNA processes through both 
the inhibition of TS and via direct misincorporation of metabolites.2  The inhibition of TS by 
FdUMP is a well-researched mechanism of DNA-based 5-FU action.  TS is an enzyme 
responsible for the synthesis of deoxythymidine monophosphate (dTMP), which is necessary for 
downstream DNA replication and repair (Figure 2).2,17  Normally, in the presence of 5,10-
methylene tetrahydrofolate (CH2-THF), TS and deoxyuridine monophosphate (dUMP) form a 
ternary complex that enables the transfer of a methyl group from CH2-THF to the C-5 position of 
dUMP, forming dTMP.  FdUMP disrupts this conversion by forming a catalytically 
nonproductive, highly stable ternary complex with TS and CH2-THF, mainly due to the tight 
binding nature of its fluorine atom to TS.6  The ensuing reduction in levels of dTMP leads to 
downstream depletion of deoxythymidine triphosphate (dTTP), which induces fluctuations in the 
levels of other deoxynucleotides (dNTPs).  Accordingly, TS inhibition therefore disrupts the 
normal ratios of dTTP, deoxyadenosine triphosphate, deoxycytidine triphosphate, and 
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deoxyguanosine triphosphate.  These imbalances disrupt DNA synthesis and repair, and are 
thought to cause severe DNA damage.1,2,6,17 
As for misincoporation of metabolites, much more is known about the cellular responses 
to DNA-based incorporation of 5-FU activity than is known about the responses to its RNA-
based mechanisms.  Generally, the combined effects of dNTP imbalance and genomic 
misincorporation are thought to result in a variety of negative consequences affecting both DNA 
synthesis and the integrity of mature DNA, which lead to the activation of cell cycle 
checkpoints.14,18  More specifically, 5-FU-induced stalled DNA replication forks or damaged 
DNA is recognized by an assortment of molecules, cuing a signaling cascade that activates the 
kinases ataxia-telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR).  
ATM and ATR then phosphorylate and activate the downstream serine and threonine checkpoint 
effector kinases, Chk1 and Chk2, which are responsible for initiating appropriate checkpoint 
responses.  Significantly, Chk1 is essential for G2 arrest, which inhibits mitosis in response to 
DNA damage, stabilizes replication forks, and coordinates 5-FU-induced DNA repair.18  5-FU 
incorporation is also thought to induce double-stranded DNA breaks, which primarily activate 
the ATM signaling pathway and lead to the blocking of cell cycle progression and mobilizing of 
DNA repair machinery.14   
In human tumor cells in vitro, misincorporated uracil and 5-FU metabolites are mainly 
removed from DNA by base excision repair (BER) pathways following the activity of uracil-
DNA glycosylases (UDGs).19  Generally, UDGs cleave an N-glycosidic bond to release the 
integrated metabolites.  The resulting abasic site in DNA can then be cleaved creating a single-
strand DNA break, which is then repaired by BER.1  Such processes have been identified in 
numerous human tumor cell lines following 5-FU administration, and very well may act to 
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protect tumor cells from DNA-directed destruction.  This could indicate DNA-based pathways 
have little to do with the anti-cancer effects of 5-FU.19     
In addition to BER, mismatch repair (MMR) is a common cellular response to 5-FU-
based DNA damage.20  MMR in human tumor cells initiates DNA re-synthesis along with 
polymerase and ligase activities, similar to those involved in BER.1  In studies, following 5-FU 
treatment, MMR improves DNA replication by correcting replication errors, such as base-to-base 
mismatches, and terminating strand exchange between mismatching sequences that occur 
following incorporation of dUTP and FdUTP.20  In these ways, MMR processes may also protect 
tumor cells from the DNA-directed effects of 5-FU treatment.   
Potential Clinical Significance of TS-Mediated DNA Mechanisms.  In vitro, a 
relationship between TS expression and DNA-mediated cytotoxicity after 5-FU treatment has 
been demonstrated in colorectal cancer cell lines according to a variety of measurement 
indicators, including TS enzyme activity, protein levels, and mRNA levels.2,6  For example, in 
colorectal tumors with low TS expression, ternary complexes of FdUMP, CH2THF, and TS were 
more efficiently formed than in tumors with high TS expression, which resulted in greater 
inhibition of DNA synthesis and increased cytotoxicity.14  Similarly, TS is overproduced in 
many 5-FU-resistant cell lines, implying that inhibition of this enzyme may be key to the 
antimetabolite’s efficacy.3  On the other hand, many other in vitro studies have shown no 
significant correlation between TS inhibition and 5-FU activity, and some have shown a negative 
correlation.  Mice with advanced colon tumors, and treated with 5-FU, had a greater chance of 
survival than those treated with another TS inhibitor.2  In human colon cancer cell lines, 
suppression of proliferation continued in similarly inhibited cells even after the addition of 
exogenous thymidine, which should negate the effects of TS inhibition, as well as after 
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simultaneous treatment with thymidine and 5-FU.2,14  In both cell lines and tumors it was also 
found that treatment with 5-FU acutely induced TS expression, and similarly, that certain high 
concentrations of thymidine actually increased 5-FU antitumor activity.21  Such findings 
complicate the conclusion that TS inhibition correlates with DNA-mediated tumor cell death.  In 
fact, since added thymidine does not always prevent the inhibitory effects of 5-FU on cell 
proliferation, and in some cases enhances cytotoxicity of the drug, there must be an alternative in 
vitro mechanism of action for 5-FU.19,21   
The clinical role of TS in human tumors treated with 5-FU is also unclear.  Patients with 
low TS gene expression in tumors have been shown to survive longer after 5-FU treatment than 
those with high tumor TS gene expression, which supports the notion that TS inhibition is critical 
to the agent’s effects in humans.15  Similarly, leucovorin (LV), which enhances TS inhibition by 
increasing the intracellular concentration of CH2THF, has been shown to improve in vivo 
response to the drug.1  In fact, a series of landmark studies by Mayo Clinic illustrated that co-
administration of 5-FU and LV improved quality of life, prolonged survival, and afforded higher 
response rates in patients as compared with 5-FU alone.10  Many other such studies have led to 
similar conclusions such that, at the present time, the combination of 5-FU and LV (with 
oxaliplatin or irinotecan) is considered standard chemotherapy for advanced colon cancer.3  
Taken together, this indicates that TS concentration and inhibition are still currently accepted to 
correlate with 5-FU’s clinical activity.   
Despite such evidence, the clinical significance of TS inhibition in patients has yet to be 
conclusively demonstrated.  Although some studies suggest that TS concentration is a predictor 
of response to fluoropyrimidine treatment, this remains controversial.  For example, in metastatic 
colon cancer, high levels of TS reflect advanced tumor progression as well as poor response to 5-
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FU.15,22  The true correlation may thus be between poor response to the drug and advanced tumor 
progression, rather than between poor response and high levels of TS.  Intrigued by such 
considerations, Showalter et al. investigated the association between 5-FU and TS expression 
with a thorough literature survey and, in contrast to previous predictions, found no connection 
between TS and patient response.22   
Potential Clinical Significance of Direct DNA Incorporation.  Several studies have 
explored incorporation of radiolabeled 5-FU and uracil metabolites into DNA using a variety of 
cell lines, cell culture systems, and human subjects.3,9,13,14,23  A majority of these studies provide 
evidence that substantial quantities of genomic 5-FU-based incorporation occurs following 
treatment, although it is not surprising that these amounts vary given the many murine and 
human, as well as in vitro and in vivo, models examined.  Although some of this research reports 
that genomic misincorporation contributes to cytotoxicity, it is still unclear how significant uracil 
incorporation or 5-FU is to cell killing.  This is mainly true because, as the rates of incorporation 
versus excision are not well determined in such studies, the interplay between misincorporation 
and DNA repair regarding cytotoxicity has yet to be established both in cell lines and 
clinically.14,17 
In fact, while 5-FU-based genomic incorporation is well-verified, the efficiency of 
subsequent DNA repair remains highly controversial both in vitro and in vivo.1  Despite a solid 
understanding of BER and much evidence that BER is activated following 5-FU administration, 
there is little known about how DNA lesions produced by uracil and 5-FU-based incorporation 
are specifically processed.19  In any case, the incorporation of dUTP and FdUTP into DNA has 
been correlated in human tumor cell lines and clinically with greater than expected levels of 
deleterious cellular effects, such as inhibition of further DNA synthesis, DNA fragmentations 
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due to single- and double-strand breaks, and mutations induced by 5-FU base pairing with 
guanine instead of adenine.24  It has also been reported that 5-FU exposure can restrain the DNA 
repair process in human tumor cell lines because of dTTP depletion, which leads to generation of 
fragmented DNA.20  Conversely, each of these points has been refuted in experiments involving 
murine and human cell lines.19,24   
Key to the controversy surrounding the effectiveness of DNA repair in 5-FU-based 
treatment, and thus the significance of DNA-based mechanisms, is the specific role of UDGs in 
human tumor cells.  Each of the four UDG types has been variably implicated in cellular 
responses to 5-FU using different model systems.1  Importantly, it has been reported that the 
enzyme uracil N-glycosylase (UNG) is responsible for most of UDG activity involved following 
5-FU treatment of human tumor cells.19,23  There is also evidence that UNG-initiated DNA repair 
protects normal and tumor cell lines through the excision of uracil and 5-FU metabolites, thus 
preventing any related effect following 5-FU therapy.24  Other in vitro evidence suggests that 
UNG initiates repair following drug treatment, but in doing so creates a more toxic lesion.  In 
this way, the repair enzyme contributes to cytotoxicity.  For example, one study reported that 5-
FU-mediated incorporation into DNA contributed to the formation of DNA strand breaks in both 
mouse bone marrow and human tumor cells, and that these breaks resulted from the removal of 
5-FU metabolites by UNG.19  In direct opposition to this research, other murine and human cell 
line studies have reported that UNG has no role in the removal of 5-FU metabolites, suggesting 
that other UDGs may be involved.24  Overall, a direct correlation between 5-FU incorporation, 
DNA repair, and cytotoxicity has yet to be established in vitro and in vivo, and thus so does the 
significance of DNA-based mechanisms in 5-FU therapy.3,6 
Methods 
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 This review was conducted as a quantitative systematic review of the scientific literature 
regarding the effects of 5-Fluoruracil in the treatment of colorectal cancer.  It began as an 
exploration of treatment duration of IV 5-FU for late stage colorectal cancer.  After finding only 
limited studies regarding treatment duration, the review was redirected to examine what appears 
to be a large question in the field.   
The greatest difficulties included limiting the number of references among the available 
research, and correlating research that addressed the mechanisms of action of 5-FU to studies in 
various models aimed at specifically addressing colorectal cancer treatment.  For included 
references, the primary outcome measure was impact on elucidating whether 5-FU exerted 
effects due to DNA or RNA-based mechanisms, which included articles that summarized the 
background of these mechanisms.    
Literature Search and Data Abstraction.  A literature search was performed using 
PubMed Central.  Articles were searched for key words 5-Fluoruacil, 5-FU, colorectal cancer, 
DNA, RNA, and mechanism of action.  The 5-Fluoruracil and 5-FU searches were crossed with 
the other search terms using the Boolean operator “AND.”  The literature search was limited to 
English language articles. 
Abstracts from searches were reviewed by a single reviewer to identify articles 
containing potential relevancy data.  Full articles were obtained for all selected abstracts and 
were further reviewed for inclusion.  The inclusion criteria applied at this step were: elucidation 
or discussion of the mechanism of action of 5-FU, use of 5-FU in cancer cell lines and animal 
models, use of 5-FU for late stage colorectal cancer in patients, and potential future uses of 5-
FU.  All full articles were also reviewed for references of interest. Abstracts and citations of 
selected references were obtained and reviewed according to the literature search procedure.  
5-Fluorouracil Treatment of Colorectal Cancer 
 
16 
This step yielded most of the research included in this article.  Finally, full articles were 
summarized, compared to one another, and organized according to relevance. 
Discussion 
Despite decades of research, the question remains as to which mechanisms are more 
important in 5-FU-based cytotoxicity, and furthermore, whether these mechanisms are the most 
important in both tumor and normal cells, both murine and human cells, and both cell lines and 
clinical models.  There are several determinants of sensitivity to 5-FU that may help to explain 
why experimentation has failed to uncover the exact cellular responses.  These include the 
model-specific availability of enzymes and co-factors involved in 5-FU metabolism and 
activation, the level of TS activity or expression, the extent of metabolite incorporation into RNA 
or DNA, and the ability of repair processes to neutralize toxic 5-FU metabolites.1,3,6,10,19  To 
complicate matters further, preclinical and clinical models suggest that toxicity, efficacy, and 
primary mechanism of action of 5-FU varies with the method and time of administration, 
whether 5-FU or a pro-drug is utilized, and which biomodulators are used in combination with 5-
FU.2,6,9,25  The following sections summarize key evaluations of the current research and propose 
solutions as to how these considerations might be addressed in in vitro, in vivo, and clinical 
models. 
Overcoming Discrepancies Among Results from Various Models.  The most obvious 
question concerning 5-FU therapy regards how the agent truly kills human tumor cells.  
Although countless studies have attempted to determine the specific mechanisms using cell lines, 
there are inherent disadvantages to this approach because lines grown in culture differ from real 
tumors in many ways.  For example, there is much evidence that numerous genetic changes 
occur during both the induction and continuation of cellular growth on media.  Another 
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disadvantage is that it is impossible to artificially mimic the environment of a tumor in vitro, as 
real tumors don’t grow in synthetic culture supplemented with animal sera.  A third problem is 
that cell lines are composed solely of tumor cells, while real tumors contain many other types.6,10   
One way to overcome these concerns would be to explore and comparatively analyze 
mechanisms by conducting a comprehensive investigation in controlled model systems using cell 
lines derived from specific tumors that are treated with 5-FU, while keeping in mind the 
limitations of cell lines.  An alternative method is to inoculate human tumors extracted from 
patients into an animal.  Although it is preferable to inoculate cells into the same tissue type in 
which the tumor originally grew, it is possible to utilize another tissue or organ.  For instance, it 
has proven worthwhile to seed human colon tumors into a mouse liver, as the liver is a common 
site of metastasis in humans.6  Such a model could then be utilized to test for specific 
mechanisms of 5-FU-based therapy, suggestions for which will be discussed below.2  Although 
these methods may be useful toward elucidating mechanisms, only clinical-based observations 
from patients will truly validate the efficacy and toxicity of 5-FU in humans. 
Elucidating the True Impact of 5-FU Incorporation into DNA.  One key 
consideration as to the importance of DNA-based pathways involves the common experimental 
use of FdUrd as a pro-drug for the elucidation of 5-FU-based mechanisms.  As FdUrd has been 
highly correlated with DNA-directed mechanisms, subsequently, so has 5-FU.  However, FdUrd 
and 5-FU vary in their pharmacological, therapeutic, and toxic attributes.  As an example of 
these differences, in experiments involving 5-FU treatment of CHO-K1 cells, DNA 
incorporation has been reported to be only about 10% of RNA incorporation.9  Conversely, 
following administration of FdUrd, DNA and RNA incorporation was approximately the 
same.9,10  Also, DNA strand breaks have been found to be more significant in FdUrd cytotoxicity 
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than 5-FU.9  Subsequently, because it has been common to equate 5-FU with its derivative for 
experimental purposes, it may be that some of the established knowledge that 5-FU has DNA-
based mechanisms of cytotoxicity are based incorrectly on experiments utilizing FdUrd.  The 
models outlined above could be utilized to more fully distinguish the effects of 5-FU from 
FdUrd, and in this way, gain a better understanding of DNA-based mechanisms regarding 5-FU.  
In any case, further analysis of both 5-FU and FdUrd may lead to both agents being more 
successfully modulated and incorporated into chemotherapeutic therapies.9 
 Elucidating the True Impact of 5-FU Incorporation into RNA.  A significant reason 
for our lack of comprehension concerning RNA-based 5-FU mechanisms is the paucity of 
research designed to elucidate these mechanisms.19  One suggestion is to conduct further studies 
in other genetic systems, which might identify novel genes, or reinforce the importance of known 
ones, involved in RNA-based effects.  For example, genetic studies in yeast have identified 
critical elements in RNA-based mechanisms, such as nuclear RNA exosome subunit Rrp6p.  
Defects in Rrp6p were shown to cause high sensitivity to 5-FU.  Research with yeast also 
indicated that although a DNA repair mutation triggered some sensitivity to treatment, Rrp6 
mutations produced significantly greater sensitivity, potentially because of drug-induced RNA 
damage.13  Such yeast genes could correlate with homologous genes in humans, which might 
have at least similar importance in 5-FU activity.  Future studies could then assess whether these 
homologous genes in humans play a role in the treatment of tumor cell lines, and ultimately, in 
real tumors.   
  Additionally, to better understand the impact of 5-FU incorporation into RNA, it would 
be best to conduct a comprehensive analysis in a tumor model system using cell lines derived 
from tumors that are treated with 5-FU, paying special attention to RNA pathways.  One 
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potential place to start is by further examining the OPRT-involved pathway through which FUTP 
is created during 5-FU anabolism.  The favored use of this pathway in certain colon cancer cell 
lines and xenograft models was shown to correlate with higher sensitivity to 5-FU.2  Such 
preliminary results indicate that this may contribute to the specialized targeting of rapidly 
dividing cells in these systems to a greater degree than DNA-based mechanisms.  Following up 
with greater research on members of this and other RNA-involved pathways may prove 
beneficial in better understanding the role of RNA misincorporation.2,19 
Conclusion 
Despite therapeutic enhancements to 5-FU treatment over previous decades, new 
strategies are still needed.  As with most chemotherapeutics, toxicity and resistance remain 
considerable limitations to its clinical use.  To predict or overcome these issues, it is essential to 
better understand the mechanisms by which this agent promotes cell death and by which tumors 
demonstrate or become resistant to it.  Accordingly, more research should be directed toward 5-
FU, especially focused on illuminating both tumor killing and normal cell toxicity pathways that 
we know little about.3 
Previously, efforts to modify 5-FU cytotoxicity have centered on lessening its 
degradation and augmenting its activation, as well as increasing overall TS inhibition.22,25  Using 
high-throughput transcriptional profiling to identify downstream signaling pathways involved in 
cellular response to 5-FU will be a key step toward bettering our understanding of 5-FU-based 
mechanisms.  In addition to identifying such interactions, high-throughput techniques may also 
identify novel therapeutic targets.  Such potential targets would first have to be evaluated using 
in vitro experimentation, perhaps by transgenic expression and antisense techniques, followed by 
studies on human tissues in animal models like those already suggested.6  Both uses of 
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transcriptional profiling will hopefully lead to the future development of combined 
chemotherapy regimens best designed to enhance the cytotoxic, and minimize the toxic, activity 
of 5-FU.   
High-throughput technology could also be used directly as a therapeutic tool.  While 
studies outlined in this review have identified some biomarkers that may predict tumor-cell 
sensitivity to 5-FU, identifying and analyzing additional factors will enhance our predictive 
capabilities even further.  As ensuing clinical trials verify these biomarkers and lead to treatment 
that is more tailored to molecular phenotypes of tumor and patient, we should see increased 
tumor response rates, decreased rates of toxicities, and lower patient care costs.1,2 
However, it is important to keep in mind that determining the functional significance of 
biomarkers regarding clinical trials requires not only rigorous analytical tools, but also thorough 
attention to data management and ethical concerns, including the meticulous tracking of amounts 
and time schedules of drug administration, patient characteristics, tumor response, adverse 
effects, and long-term follow-up.2  Also, because many biomarkers are likely to affect the 
outcomes of anticancer drug therapy, clinical trials should include large numbers of patients to 
produce meaningful results.  If current trials include appropriate collection and storage of patient 
samples, documentation of therapy and results, and adequate study design, future analyses may 
be able to test which variants are predictive of anticancer outcome.6  Perhaps in the coming 
years, clinical trials that target 5-FU therapy based on each patient's individual genetic 
constitution will be able to test whether such individualization truly benefits patients. 
Indeed, the advent of high-throughput transcriptional profiling may have enormous 
therapeutic implications for cancer therapy.  A better understanding of the molecular 
determinants of sensitivity to 5-FU may lead to more rationally designed treatment 
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combinations, the detection of new biomarkers and therapeutic targets, and enable the 
individualization of 5-FU-based patient treatment.6  It is conceivable that, soon, high-throughput 
techniques will be available for routine use in a clinical setting, and diagnosis and treatment of 
associated cancers will be tailor-made according to the expression profile of each patient.  For 
now, our first step is to further our understanding of the mechanisms of 5-FU efficacy. 
 
 





1.  Wyatt MDM. Participation of DNA repair in the response to 5-fluorouracil. Cellular and 
molecular life sciences: CMLS. 2009;66(5):788-99. 
 
2.  Longley Daniel BD. 5-fluorouracil: Mechanisms of action and clinical strategies. Nature 
Reviews Cancer. 2003;3(5):330-8. 
 
3.  Temraz Sally S. Methods of overcoming treatment resistance in colorectal cancer. Crit 
Rev Oncol. 2014;89(2):217-30. 
 
4.  Des Guetz Gaëtan G. Duration of adjuvant chemotherapy for patients with non-metastatic 
colorectal cancer. The Cochrane database of systematic reviews. 2010(1). 
 
5.  Heidelberger CC. The comparative utilization of uracil-2-C14 by liver, intestinal mucosa, 
and flexner-jobling carcinoma in the rat. Cancer Res. 1957;17(5):399-404. 
 
6.  Rich Tyvin AT. Four decades of continuing innovation with fluorouracil: Current and 
future approaches to fluorouracil chemoradiation therapy. Journal of Clinical Oncology. 
2004;22(11):2214-32. 
 
7.  Corbett THT. Evaluation of single agents and combinations of chemotherapeutic agents 
in mouse colon carcinomas. Cancer. 1977;40(5):2660-80. 
 
8.  Carethers John MJ. Use of 5-fluorouracil and survival in patients with microsatellite-
unstable colorectal cancer. Gastroenterology. 2004;126(2):394-401. 
 
9.  van Laar, J A JA. Comparison of 5-fluoro-2'-deoxyuridine with 5-fluorouracil and their 
role in the treatment of colorectal cancer. Eur J Cancer. 1998;34(3):296-306. 
 
10.  Miura Koh K. 5-fu metabolism in cancer and orally-administrable 5-fu drugs. Cancers. 
2010;2(3):1717-30. 
 
11.  Calabro-Jones PMP. Time-dose relationships for 5-fluorouracil cytotoxicity against 
human epithelial cancer cells in vitro. Cancer Res. 1982;42(11):4413-20. 
 
12.  Lonardi SS. Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in 
stage II-III colon cancer: Safety and compliance in the TOSCA trial. Annals of Oncology. 
2017. 
 
13.  Silverstein Rebecca AR. The incorporation of 5-fluorouracil into RNA affects the 
ribonucleolytic activity of the exosome subunit Rrp6. Molecular Cancer Research. 
2011;9(3):332-40. 
 
5-Fluorouracil Treatment of Colorectal Cancer 
 
23 
14.  Noordhuis PP. 5-fluorouracil incorporation into RNA and DNA in relation to thymidylate 
synthase inhibition of human colorectal cancers. Annals of Oncology. 2004;15(7):1025-
32. 
 
15.  Koehler Sara ES. Small interfering RNA-mediated suppression of dUTPase sensitizes 
cancer cell lines to thymidylate synthase inhibition. Mol Pharmacol. 2004;66(3):620-6. 
 
16.  An Qian Q. 5-fluorouracil incorporated into DNA is excised by the Smug1 DNA 
glycosylase to reduce drug cytotoxicity. Cancer Res. 2007;67(3):940-5. 
 
17.  Sobrero AFA. Fluorouracil in colorectal cancer--a tale of two drugs: Implications for 
biochemical modulation. Journal of Clinical Oncology. 1997;15(1):368-81. 
 
18.  Robinson, H M R HM. Chk1-dependent slowing of S-phase progression protects DT40 
B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene. 
2006;25(39):5359-69. 
 
19.  Pettersen Henrik Sahlin, H S. UNG-initiated base excision repair is the major repair route 
for 5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends mainly on RNA 
incorporation. Nucleic Acids Res. 2011;39(19):8430-44. 
 
20.  Kunz Christophe C. Base excision by thymine DNA glycosylase mediates DNA-directed 
cytotoxicity of 5-fluorouracil. PLoS Biology. 2009;7(4). 
 
21.  Brody Jonathan RJ. Limits to thymidylate synthase and TP53 genes as predictive 
determinants for fluoropyrimidine sensitivity and further evidence for RNA-based 
toxicity as a major influence. Cancer Res. 2009;69(3):984-91. 
 
22.  Showalter Shayna LS. Evaluating the drug-target relationship between thymidylate 
synthase expression and tumor response to 5-fluorouracil. is it time to move 
forward? Cancer Biology Therapy. 2008;7(7):986-94. 
 
23.  Huehls Amelia MA. Genomically incorporated 5-fluorouracil that escapes UNG-initiated 
base excision repair blocks DNA replication and activates homologous 
recombination. Mol Pharmacol. 2016;89(1):53-62. 
 
24.  Fortini Paola P. Base damage and single-strand break repair: Mechanisms and functional 
significance of short- and long-patch repair subpathways. DNA Repair. 2007;6(4):398-
409. 
 
25.  Thomas DMD. 5-fluorouracil: A pharmacological paradigm in the use of 









Figure 1: Metabolism of 5-fluorouracil.2 
 
 
Figure 2: Mechanism of thymidylate synthase inhibition by 5-fluorouracil. 

